Ivan Martin studied Biomedical Engineering at the University of Genova where he obtained his PhD in 1996. Between 1996 and 1999 he was a postdoctoral associate at Harvard/MIT. He joined the Department of Biomedicine at the University of Basel in 1999 as Director of the Tissue Engineering Research Group. In 2007 he was appointed Professor for Tissue Engineering. From 2004 to 2009 he was the first chair of the European section of the Tissue Engineering Regenerative Medicine International Society (TERMIS). He is currently member of the editorial boards of 5 international journals and of the ‘Mesenchymal stem cell committee of the International Society for Cellular Therapy (ISCT). His group includes scientists from the biological, engineering and clinical fields, dedicated to develop scientific basis for innovative translational strategies in regenerative medicine. In this field he is author of 250+ peer-reviewed papers on international journals and inventor on 10+ patent applications, with a H-index of 86. The developed science and technology have been translated into three clinical trials for cell-based cartilage and bone repair (see Fulco+, Lancet 2014; Pelttari+, Sci Transl Med 2014; Mumme+, Lancet 2016), and into the founding of a spin-out company for the commercialization of tissue culture bioreactors (Cellec Biotek AG).